Reminder: FDA's FIRST Authorized AI in Any Field of Medicine Was for Diabetic Retinopathy (IDx-DR / LumineticsCore, April 2018)
Strategic context: vision is the bow wave of clinical AI adoption — not radiology, not pathology, not ambient documentation. The FIRST FDA De Novo authorized autonomous AI in the entire history of US medicine was IDx-DR (now LumineticsCore from Digital Diagnostics) in April 2018, for diabetic retinopathy detection in primary care.
87.2% sensitivity / 90.7% specificity. Two more autonomous AI systems followed: EyeArt (Eyenuk, 2020 — 96% sens / 88% spec for mtmDR), and AEYE-DS (AEYE Health, 2022 — 93% / 91.4%, expanded 2024 for handheld portable).
Plus SCANLY Home OCT (Notal Vision, May 2024) — first FDA-authorized patient-self-operated home OCT. Cahaba Medical Care (AL FQHC) deployment data: AI identified previously-missed DR in >1-in-4 patients screened. CA documented FQHC adopters: Tarzana Treatment Centers (LumineticsCore), San Ysidro Health (EyeArt RCT).
Primary source
FDAAffected FQHCs
FQHC Talent. (2018, April 11). Reminder: FDA's FIRST Authorized AI in Any Field of Medicine Was for Diabetic Retinopathy (IDx-DR / LumineticsCore, April 2018). Primary source: FDA. Retrieved June 15, 2026, from https://www.fqhctalent.com/intel/fda-first-medical-ai-was-diabetic-retinopathy-2018
More in Strategy & Tactics
Jun 1
Redding's Sunrise Mountain Wellness Center Closes June 30 — a Third Prop 1 / BHSA Peer-Support Closure in the North State
Jun 1
Lake County Closes 3 Prop 1 Peer Support Centers June 1 — Including the County's Only Tribal-Specific Mental-Health Hub
May 14
eClinicalWorks Launches healowIQ + AI Workbench + healow Genie at FQHC-Dedicated Health Center Summit
May 7
Artera Launches AI Services Model + Agentic AI Squads — First Vendor to Package Agentic AI for 300 FQHC Customer Base